IN THE CLAIMS:

~~Patent claims.~~ CLAIMS

1. (Currently Amended) A method for the prophylaxis or treatment of at least one viral disease comprising administering a physiologically effective dose of a pharmaceutical composition comprising~~The use of~~ at least one active ingredient inhibiting a component of the NF-kB signal transduction pathway such that a virus multiplication is inhibited~~, for preparing a pharmaceutical composition for the prophylaxis and/or therapy of at least one viral disease~~.

2. (Currently Amended) ~~The use of at least one active ingredient according to~~ The method of claim 1, wherein the component of the NF-kB signal transduction pathway is selected from the group consisting of [[""]]tumor necrosis factor receptor associated factor (TRAF), NF-kB inducing kinase (NIK), mitogen-activated protein kinase kinase kinase 1 (MEKKK1), mitogen-activated protein kinase kinase kinase 3 (MEKKK3), AKR mouse thymoma kinase (AKT), TGFβ activated kinase (TAK1), inhibitor of NF-kB kinase alpha (IKKalpha), inhibitor of NF-kB kinase beta (IKKbeta), NEMO, inhibitor of kB (IkB), RELA (p65), C-REL, RELB, NF-kB1 (p105), NF-kB2 (p100), P50, and P52[[""]].

3. (Currently Amended) ~~The use of at least one active ingredient according to one of claims 1 to 2,~~ The method of claim 1, wherein the active ~~ingredient(s) is (are)~~ ingredients are selected from the group consisting of [[""]]inhibitors of a kinase of the NF-kB signal transduction pathway, e.g. nonsteroidal anti-inflammatory substances inhibiting the NF-kB activation, ~~such as~~ comprising phenylalkyl acid derivatives, ~~for instance~~ sulindac, or derivatives of sulindac ~~such as~~ comprising sulindac sulphoxide, sulindac sulphone, sulindac sulphide or benzylamide sulindac analogues, salicylic acid derivatives ~~such as~~ comprising salicylic acid or acetylsalicylic acid, salcylamide, salacetamide, ethenzamide, diflunisal, olsalazine or salazosulfapyridine, curcumin, antioxidants ~~such as~~ comprising pyrrolidine dithiocarbamate (PDTC), oxicams ~~as for instance~~ comprising piroxicam, vitamin E and derivatives thereof~~, such as~~ comprising pentamethyl hydroxychroman (PMC), 17 beta oestradiol and derivatives thereof, polyphenoles of tea ~~as for instance~~ comprising (-)-epigallo-catechin-3-gallate (EGCG), Bay11-7182, peptides inhibiting the interaction of at

least two components of the NF-kB signal transduction pathway, ~~for instance~~ comprising peptides binding to NEMO, inhibitors of ~~the~~ a proteosome ~~such as~~ comprising PS-341 and lactacystin, antisense oligonucleotides specifically adding to the DNA sequence or m-RNA sequence coding for a component of the NF-kB signal transduction pathway and inhibiting the transcription or translation thereof, ~~for instance~~ comprising antisense nucleotide sequences specific for p65 or p50, dominant-negative mutants of a component of the NF-kB signal transduction pathway, ~~dsoligonucleotides~~ ds-oligonucleotides, ~~which are~~ suitable for the specific degradation of the mRNAs of a component of the NF-kB signal transduction pathway by the RNAi technology, antibodies or antibody fragments specific for a component of the NF-kB signal transduction pathway, or fusion proteins, containing at least one antibody fragment~~, for instance~~ comprising a Fv fragment[[,]] which inhibits at least one component of the NF-kB signal transduction pathway[["]].

4. (Currently Amended) The method of claim 1~~The use of at least one active ingredient according to one of claims 1 to 3~~, wherein the viral disease is caused by an infection by RNA or DNA viruses~~, preferably~~ comprising influenza viruses.

5. (Currently Amended) A combination preparation for the prophylaxis ~~and/~~or therapy of at least one viral disease[[,]] comprising at least two different active ingredients, wherein at least one active ingredient is selected from the group according to claim 3, wherein the combination preparation ~~can be used~~ is in the form of a mixture or ~~as~~ individual components for ~~the~~ simultaneous or ~~not~~ non-simultaneous application at identical or different ~~places~~ administration sites.

6. (Original) A combination preparation according to claim 5, wherein at least one antivirally acting substance is 1-adamantanamine, rimantadine, a neuraminidase inhibitor or a nucleoside analogue such as ribavirin.

7. (Currently Amended) A method for the prophylaxis or therapy of an infection by negative-strand RNA viruses comprising influenza viruses or Borna viruses, comprising administering a

physiologically effective dose of the combination preparation of claim 5 ~~The use of an active ingredient or of a combination preparation according to one of claims 1 to 6 for the prophylaxis and/or therapy of an infection by negative-strand RNA viruses, in particular influenza viruses or Borna viruses~~.

8. (Currently Amended) The method of claim 7, wherein the preparation is administered nasally, bronchially, or aerogenically, and ~~The use of an active ingredient or of a combination preparation according to one of claims 1 to 7 in a preparation for the nasal, bronchial or aerogenic administration,~~ wherein the active ingredient is present in a concentration from 0.1 to 4 mM in the preparation, wherein the total amount of the active ingredient per administration unit is ~~preferably~~ in the range of 0.1 to 70 mg, wherein the pharmaceutical composition is prepared ~~and confectioned such that the~~ for a daily dose ~~for man does not exceed~~ of less than or equal to 70 mg.

9. (Currently Amended) A test system for identifying active ingradients[[,]] which act on at least one component of the NF-kB signal transduction pathway such that a virus multiplication is substantially inhibited[[,]] comprising a)[[.]] at least one cell ~~infectible~~ infectible by at least one virus, said cell containing the NF-kB signal transduction pathway and at least one virus infecting the cells, or b)[[[.]] at least one cell infected by at least one virus, said cell overexpressing the NF-kB signal transduction pathway.

10. (Currently Amended) A test system according to claim 9, wherein the virus is an RNA or DNA virus~~, preferably~~ comprising an influenza virus.

11. (Currently Amended) A test system according to claim 9 ~~or 10~~, wherein the cell contains at least one overexpressed component of the NF-kB signal transduction pathway~~, also~~ in a constitutively active mutated form.

12. (Currently Amended) A test system according to ~~one of claims 9 to 12~~ claim 9, wherein ~~it contains a cell, in which~~ at least one gene coding for at least one dominant-negative mutant of at least one component of the NF-kB signal transduction pathway is overexpressed by the cell.

13. (Currently Amended) A test system according to ~~one of claims 9 to 12~~ claim 9, wherein ~~it contains a cell, in which~~ the expression for at least one component of the NF-kB signal transduction pathway is overexpressed in the cell.

14. (Currently Amended) A method for identifying at least one active ingredient for the prophylaxis ~~and/~~or therapy of viral diseases, said active ingredients substantially inhibiting the multiplication of viruses in viral diseases, comprising the following steps: a)[[.]] bringing at least one potential active ingredient into contact with at least one test system according to ~~one of claims 9 to 13~~ claim 9, b)~~. determination of~~ determining the effect on the virus multiplication, and c)~~. selection of~~ selecting a potential active ingredient[[,]] if the virus multiplication is reduced compared to an execution of step a)~~., however~~ without a potential active ingredient or with an active reference ingredient or with a control substance.

15. (Currently Amended) A method for preparing a drug for the prophylaxis ~~and/~~or therapy of at least one viral disease, said drug inhibiting the multiplication of viruses in the case of viral diseases, comprising the following steps: a)[[.]] executing a test system according to ~~one of claims 9 to 14~~ claim 9, b)[[.]] reacting the identified active ingredient(s) in a physiologically effective dosage with at least one auxiliary ~~and/~~or additional substance and a defined galenic preparation.